Republic Services Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Republic Services Inc. Common Stock trades at $227 (market cap $68.73B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.50B). The key difference: Republic Services Inc. Common Stock is far larger — about 3.9× Zimmer Biomet Holdings Inc's market cap, and Republic Services Inc. Common Stock pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| RSG | ZBH | |
|---|---|---|
Market Cap | $68.73B | $17.50B |
Volume | 1,226,777 | 1,890,029 |
Sector | Industrials | Health |
52-Week High | $232.27 | $103.98 |
52-Week Low | $197.73 | $79.58 |
Enterprise Value | $82.91B | $24.57B |
Dividend Yield | 1.19% | 1.05% |
Typical Hold Time | — | 89 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $92.08, down 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 8.56%. A quarterly dividend of $0.24 was recently declared, payable in October 2026.
The investment outlook is cautiously optimistic, driven by earnings beats and analyst consensus pointing to upside. Key risks include rising debt levels and competitive pressures. The consensus price target of $103.11 suggests potential appreciation, but investors should weigh margin trends and macroeconomic factors affecting healthcare spending.
Trailing returns across standard periods
Latest headlines on both assets
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →